Chinese biotech's out-licensing boom hits a wall as drug giants tighten budgets
Record cross-border deals flipped loss-making Chinese biotechs to profit, but tightening Big Pharma budgets could slam the funding door shut.
By Khalid Al-Harbi·· 3 min
Loading the Newsroom
Curating from trusted global sources…